

### Amendments to the Claims

**1. (Currently amended)** A vector for trapping an unknown gene of *Drosophila melanogaster*, which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic stop/start sequence;

a reporter gene;

a promoter directed drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site.

**2. (Currently amended)** The vector of claim 1, wherein the recombinant plasmid is ~~derived from pCasper3~~ made by inserting the promoter directed drug resistance gene into pCasper3.

**3. (Previously amended)** The vector of claim 1, wherein the reporter gene is the Gal4 gene.

**4. (Currently amended)** The vector of claim 3, which vector has the nucleotide sequence of SEQ ID No. 1.

**5. (Previously presented)** The vector of claim 1, wherein the reporter gene is Gal4 DNA binding domain-P53 fusion gene.

**6. (Previously presented)** The vector of claim 1, wherein the reporter gene is the Gal4-firefly luciferase fusion gene.

**7. (Previously presented)** The vector of claim 1, wherein the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene.

**8. (Previously presented)** The vector of claim 1, wherein the drug resistance gene is neomycin-phosphotransferase gene and its the resistance gene promoter is a heatshock promoter.

**9. (Currently amended)** A vector ~~derived from pCasperhs, which has the~~ made by inserting a heatshock promoter directed Gal4 activator domain-large T antigen fusion gene ~~within into the~~ polycloning site of the pCasperhs.

**10. (Currently amended)** A method for trapping an unknown gene of *Drosophila melanogaster* by using a vector which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic stop/start sequence;

a reporter gene;

a promoter directed drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site,

which method comprises the steps of:

- (a) introducing the vector into the genome of a white minus fly;
- (b) selecting primary transformants resistant to a drug to which transformants having the drug resistance gene are survivable;
- (c) crossing the primary transformants with a transposase source strain to force the vector to jump into other locations;
- (d) selecting secondary transformants by picking up the flies having strong eye color,

- (e) crossing the secondary transformants with UAS (Upstream Activator Sequence)-luciferase harboring strain and measuring the reporter gene expression of the resultant flies; and
- (f) identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.

**11. (Currently amended)** The method according to claim 10, wherein the recombinant plasmid is ~~derived from pCasper3~~ made by inserting the promoter directed drug resistance gene into pCasper3.

**12. (Previously presented)** The method according to claim 10, wherein the reporter gene in the vector is the Gal4 gene, and in the step (e) the Gal4 expression is measured.

**13. (Previously presented)** The method according to claim 10, wherein the reporter gene of the vector is the Gal4-firefly luciferase fusion gene, and in the step (e) expression of said fusion gene is measured without crossing the secondary transformants with UAS-luciferase harboring strain.

**14. (Previously presented)** The method according to claim 10, wherein the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene, and in the step (f) the cDNAs fused to the reporter gene and the mini-white gene are cloned and sequenced.

**15. (Currently amended)** The method according to claim 10, wherein the drug resistance gene is neomycin-phosphotransferase gene and it's the resistance gene promoter is a heatshock promoter, and in the step (b) the transformants resistant to G418 ~~is~~ are selected.

**16. (Withdrawn)**

A method for trapping an unknown gene of *Drosophila melanogaster* by using a vector A which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic top/start sequence;

Gal4 DNA binding domain-P53 fusion gene as a reporter gene;

a drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site,

and a vector B derived from pCasperhs, which has the heatshock promoter directed Gal4 activator domain-large T antigen fusion gene within polycloning site of the pCasperhs,

which method comprises the steps of:

- (a) introducing each of the vectors A and B into the genomes of separate white minus flies;
- (b) selecting primary transformants for the vector A which are resistant to a drug, and selecting primary transformants for the vector B which have an eye color;
- (c) crossing the primary transformants for the vector A with a transposase source strain to force the vector to jump into other locations;
- (d) selecting secondary transformants for the vector A by picking up the flies having strong eye color;
- (e) crossing the secondary transformants with the primary transformants for the vector B to obtain flies harboring both the vectors A and B;
- (f) crossing the flies obtained in the step (e) with an UAS-luciferase harboring fly strain and measuring the reporter gene expression of the resultant flies after a heatshock treatment; and
- (g) identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.

**17. (Withdrawn)**  
derived from pCasper3.

The method according to claim 16, wherein the vector A is

**18. (Withdrawn)**  
The method according to claim 16, wherein the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene, and in the step (g) the cDNAs fused to the reporter gene and the mini-white gene are cloned and sequenced.

**19. (Withdrawn)**  
The method according to claim 16, wherein the drug resistance gene is neomycin-phosphotransferase gene and its promoter is a heatshock promoter, and in the step (b) the transformant resistant to G418 is selected.